Selank: Real Clinical Trials, One Country, No Replication

Selank is sold online as an anxiolytic peptide, and unlike most compounds in that market it has been tested in patients with a diagnosis. A comparative study of 62 people with generalized anxiety disorder and neurasthenia set selank against medazepam, a benzodiazepine, using standard psychometric scales. The anxiolytic effects of the two were reported as similar, with selank also showing antiasthenic and psychostimulant effects.^[1] The trial is from 2008, it is published in Russian, and it has not been independently replicated in the English-language literature.

What the study reported

Sixty-two patients were studied: 30 received selank and 32 received medazepam. State was assessed with the Hamilton and Zung scales and the Clinical Global Impression. Alongside the clinical measures the researchers took a biological one, measuring enkephalin activity in blood serum.^[1]

• Anxiolytic effect: reported as similar between selank and the benzodiazepine comparator.
• Selank additionally showed antiasthenic and psychostimulant effects, which the benzodiazepine did not.
• Patients with these diagnoses had a decreased level of a leu-enkephalin parameter, correlated with disease duration and symptom severity.
• That parameter rose during selank treatment, most clearly in the generalized anxiety group.

The study’s strongest design feature is its active comparator. Testing a new compound against a drug already known to work is a harder test than testing it against placebo.

What is missing, and why it matters more than what is there

The evidence base for selank sits almost entirely in one national literature, produced largely around the institute that developed the compound. That implies nothing improper; it is the ordinary situation for a drug that never went through a Western regulatory program. But independent replication is the mechanism by which a promising early result becomes a reliable one, and for selank that step has not happened. Epitalon, from a different St. Petersburg institute, shows the same pattern.

“Published in Russian” is not a reason to discard a study. Plenty of good science is published outside English. The problem is narrower and harder: one source of evidence, in one place, without outside replication, is a weak foundation regardless of which country it comes from, the United States included.

Selank’s evidence comes almost entirely from one national literature, largely from its developers’ institute, and no independent replication has been published.

What that means if you are considering it

• Selank is not an approved medicine in the United States, and what is sold here is a research chemical, outside the manufacturing and labeling standards that apply to prescription drugs.
• Selank is not one of the six peptides in the interim compounding policy HHS announced on October 28, 2026, which does cover semax, and FDA lists selank acetate among substances whose nominations were withdrawn from its safety-risk Category 2.^[2][3]
• What you buy under that name has no guarantee of identity, purity or dose. That is a separate problem from whether the molecule works.
• The clinical evidence is real but thin, single-source and unreplicated.
• Generalized anxiety disorder has treatments with large, replicated, independent evidence bases. Substituting an unapproved peptide for them is a decision worth discussing with a clinician rather than a forum.

For the regulatory position on research-use peptides generally, see what FDA actually said about BPC-157. For how selank differs from semax under the October 2026 HHS policy, see Semax vs Selank. Selank's compounding status, evidence grade and the sellers we track are on our selank profile, and the other profiles are listed at /peptides.